Latest news

• BMS psoriasis drug hits the mark in phase II

  including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.

• Boehringer beefs up biologics capacity with €230m investment

  That includes its portfolio of biosimilar drugs, as well as novel candidates such as AbbVie-partnered interleukin-23 inhibitor risankizumab – in phase III trials in psoriasis and psoriatic arthritis – and

• UK, Germany back routine use of J&J’s Tremfya

  J&J is facing the threat of direct competition to Tremfya, however, as rival AbbVie’s IL-23 inhibitor risankizumab which - according to some analysts - might have an edge in terms

• Sun Pharma passes milestone with novel psoriasis drug approval

  Meanwhile, AbbVie has an IL-23 blocker called risankizumab in late-stage testing that it thinks could be a best-in-class treatment and a $1bn-plus contender in psoriasis.

• AbbVie reports more solid data for would-be psoriasis blockbuster

  Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara. ... suggested trials to date show risankizumab might be a little better than its rival with the potential for less frequent dosing.